Spruce Biosciences (SPRB) EBT Margin (2023 - 2024)
Spruce Biosciences (SPRB) posted quarterly EBT Margin of 3368.29% for Q4 2024, down 297978.0% year-over-year from N/an in Q1 2024, and down 133.07% quarter-over-quarter from 1445.17% in Q3 2024.
Spruce Biosciences (SPRB) EBT Margin (2023 - 2024) Analysis & Trends
Spruce Biosciences (SPRB) has reported EBT Margin for 2 consecutive years, with 3368.29% the latest figure, recorded in Q4 2024.
- In Q4 2024, EBT Margin fell 297978.0% year-over-year to 3368.29%; the TTM figure through Sep 2025 stood at 6880.2% (down 630715.0% YoY), while the FY2024 annual figure was 1080.7%, down 54124.0% from the prior year.
- EBT Margin slipped to 3368.29% in Q4 2024 per SPRB's latest filing, from 1445.17% in the prior quarter.
- Across five years, EBT Margin topped out at 388.52% in Q4 2023 and bottomed at 3368.29% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -3,368.29% |
| Sep 30, 2024 | -1,445.17% |
| Jun 30, 2024 | -570.25% |
| Mar 31, 2024 | -581.25% |
| Dec 31, 2023 | -388.52% |
| Sep 30, 2023 | -446.63% |
| Jun 30, 2023 | -634.82% |
| Mar 31, 2023 | -652.40% |